This week marks the two-year anniversary of the BiotechDueDiligence website and my @BioDueDiligence Twitter feed. Back then I was a post-doc with a hobby-sized brokerage account, a laptop full of SEC filings, spreadsheets, slide decks, and journal articles plus a few notebooks of illegible notes from webcasts and telephone conversations. I thought I would use a website to organize my thoughts on various biotech stocks, and if a few other people found it useful, so much the better. I had no expectations, but the journey from that day to where I am now would have blown away any aspirations I could have had.
Despite changing day jobs twice, becoming a father, and losing some hair since then, I am still pretty much that same guy who would happily spend any day researching and talking about all things biotech with anyone and everyone within "earshot" of my voice, tweets, blog entries, or websites.
(Continue reading after the jump)
Who mkaes up the BiotechDueDiligence audience? You are friends, colleagues, day traders, professional investors and analysts, scientists, clinicians, consultants, journalists, students, patients, care-givers, or some combination thereof. You are from up the road, across the U.S., and around the globe. You read the site from your iPhone, your home, the beach, universities, pharmacetuical/biotech companies, and Wall Street institutions. Each of you finds some value in my work, and I am grateful for that. There are realtively few of you who i have spoken to on the phone or met in person, hopefully this number will continue to increase in 2013 and beyond.
To those who retweet, favorite, reply, forward, #FF and whatever else even though I am horrible about acknowledging you and reciprocating, thank you.
To those few who have taken the time to send a personal note or make a contribution, thank you for helping keep me inspired to create, maintain, and improve this resource for biotech enthusiasts.
To those that have contributed the time, effort, and talent to help make a small portion of BiotechDueDiligence a better resource for us all, thank you.
Finally, though I won't single you out by name here, there are a few of you that deserve individual gratitute. I have interacted with most of you since the very start of BiotechDueDiligence: a fund manager who recognized someone on a similar career trajectory and offered guidance, a professional analyst who always has time for encouragement, stock questions and career advice, high-profile writers/bloggers who gave personal advice on chasing a touchy story and continually engaged with me when you didn't have to, (former) strangers who have recognized my efforts and reached out about potential new endeavors, and a warm-hearted trader who is both fun to chat with and the site's biggest booster.
BiotechDueDiligence has already changed a great deal over the past two years and will continue to evolve. Here is what you can expect going forward:
- You will always get my unbiased view on the latest newsflow in biotech. I am largely prohibited from trading biotech stocks, so I will never be talking my book.
- If you are looking for buy/sell recommendations, you've probably come to the wrong place, though I will let you know when I think a stock is cheap or overvalued.
- I have a finely tuned BS detector, (un)healthy levels of cynicism and sarcasm, and little tolerance for incompetent or disingenous management. Adjust accordingly.
- The number one goal of the site is to make you a better biotech investor, observer, etc. I will connect you to the people, resources, techniques, and advice to make this happen, no matter the source.
- I will try to help you better understand the role of my current employer in the biopharma drug development process to the greatest extent possible. However, there will always be some topics I cannot discuss and questions I will not answer. Gotta keep food on the table, so I hope you understand.
- I will provide due diligence materials on drugs, clinical trials, and companies that are timely, popular, or simply of interest to me. However, I cannot feasibly be a continuous and complete encyclopedia of information about all companies covered on the site.
I don't know exactly what the next two years will hold, but I know that none of my upcoming opportunities and challenges would have happened without the interations with and support from all of you that make up the BiotechDueDiligence community.
In closing, thanks for reading and for your support of BiotechDueDiligence. Please reply by blog comment, email or the Contact form to let me know of any suggestions or to tell me which areas of the site are most useful and deserve continued attention.
If you are so inclined, please consider various ways in which you can show your support for the time and effort that I have and will continue to invest in the site. Contributions in any amount are graciously appreciated.